GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Labcorp Holdings Inc (NYSE:LH) » Definitions » Gross Profit

LH (Labcorp Holdings) Gross Profit : $3,624 Mil (TTM As of Dec. 2024)


View and export this data going back to 1991. Start your Free Trial

What is Labcorp Holdings Gross Profit?

Labcorp Holdings's gross profit for the three months ended in Dec. 2024 was $896 Mil. Labcorp Holdings's gross profit for the trailing twelve months (TTM) ended in Dec. 2024 was $3,624 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Labcorp Holdings's gross profit for the three months ended in Dec. 2024 was $896 Mil. Labcorp Holdings's Revenue for the three months ended in Dec. 2024 was $3,329 Mil. Therefore, Labcorp Holdings's Gross Margin % for the quarter that ended in Dec. 2024 was 26.92%.

Labcorp Holdings had a gross margin of 26.92% for the quarter that ended in Dec. 2024 => Competition eroding margins

During the past 13 years, the highest Gross Margin % of Labcorp Holdings was 38.01%. The lowest was 27.67%. And the median was 29.94%.

Warning Sign:

Labcorp Holdings Inc gross margin has been in long-term decline. The average rate of decline per year is -2.8%.


Labcorp Holdings Gross Profit Historical Data

The historical data trend for Labcorp Holdings's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Labcorp Holdings Gross Profit Chart

Labcorp Holdings Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4,952.80 4,992.40 3,708.90 3,364.90 3,624.40

Labcorp Holdings Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 821.40 897.30 926.40 904.40 896.30

Competitive Comparison of Labcorp Holdings's Gross Profit

For the Diagnostics & Research subindustry, Labcorp Holdings's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Labcorp Holdings's Gross Profit Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Labcorp Holdings's Gross Profit distribution charts can be found below:

* The bar in red indicates where Labcorp Holdings's Gross Profit falls into.


;
;

Labcorp Holdings Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Labcorp Holdings's Gross Profit for the fiscal year that ended in Dec. 2024 is calculated as

Gross Profit (A: Dec. 2024 )=Revenue - Cost of Goods Sold
=13008.9 - 9384.5
=3,624

Labcorp Holdings's Gross Profit for the quarter that ended in Dec. 2024 is calculated as

Gross Profit (Q: Dec. 2024 )=Revenue - Cost of Goods Sold
=3329.4 - 2433.1
=896

Gross Profit for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $3,624 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Labcorp Holdings's Gross Margin % for the quarter that ended in Dec. 2024 is calculated as

Gross Margin % (Q: Dec. 2024 )=Gross Profit (Q: Dec. 2024 ) / Revenue (Q: Dec. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=896 / 3329.4
=26.92 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Labcorp Holdings  (NYSE:LH) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Labcorp Holdings had a gross margin of 26.92% for the quarter that ended in Dec. 2024 => Competition eroding margins


Labcorp Holdings Gross Profit Related Terms

Thank you for viewing the detailed overview of Labcorp Holdings's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Labcorp Holdings Business Description

Traded in Other Exchanges
Address
358 South Main Street, Burlington, NC, USA, 27215
Labcorp is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing.
Executives
Kerrii B Anderson director WENDY'S INTERNATIONAL, INC, 4288 WEST DUBLIN-GRANVILLE RD., DUBLIN OH 43017
Mark S Schroeder officer: EVP, President-Diagnostics Lab 531 SOUTH SPRING STREET, BURLINGTON NC 27215
Van Der Vaart Sandra D officer: SVP, Global General Counsel 531 SOUTH SPRING STREET, BURLINGTON NC 27215
Amy B. Summy officer: EVP, Chief Marketing Officer 531 SOUTH SPRING STREET, BURLINGTON NC 27215
Adam H Schechter director 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Dwight Gary Gilliland director 531 SOUTH SPRING STREET, BURLINGTON NC 27215
Glenn A Eisenberg officer: Chief Financial Officer, EVP P O BOX 1017, CHARLOTTE NC 28201-1017
Lance Berberian officer: SVP, Chief Information Officer
Peter J Wilkinson officer: SVP, Chief Accounting Officer C/O PHARMACEUTICAL PRODUCT DEVELOPMENT, 929 NORTH FRONT STREET, WILMINGTON NC 28401
Paul Rothman director 6 MEADOW ROAD, BALTIMORE MD 21212
Paul R Kirchgraber officer: CEO, Covance Drug Development 531 SOUTH SPRING STREET, BURLINGTON NC 27215
Megan D. Bailey officer: EVP, Chief Strategy Officer 531 SOUTH SPRING STREET, BURLINGTON NC 27215
Jonathan P. Divincenzo officer: EVP, Pres, Central Labs & Intl 940 WINTER STREET, PERKINELMER, INC. LEGAL DEPARTMENT, WALTHAM MA 02451
Anita Z Graham officer: EVP, CHRO C/O THE ADT CORPORATION, 1501 YAMATO ROAD, BOCA RATON FL 33431
Thomas Pike officer: Pres & CEO Clinical Business C/O ACCENTURE, 161 N. CLARK STREET, 23RD FLOOR, CHICAGO IL 60601